|Summary sheet: 5-MeO-DiPT|
|Common names||5-MeO-DiPT, "Foxy Methoxy", "Foxy"|
|Routes of Administration|
5-Methoxy-N,N-diisopropyltryptamine (also known as 5-MeO-DiPT, Foxy, and Foxy Methoxy) is a novel psychedelic substance of the tryptamine class that produces psychedelic effects when administered. It is related in structure to DiPT and 5-MeO-MiPT.
The first human trials of 5-MeO-DiPT were undertaken by Alexander Shulgin in 1975. who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981. A summary of the synthesis and reports of human use is included in Shulgin's 1997 book TiHKAL ("Tryptamines I Have Known And Loved").
Anecdotal reports characterize the effects of this compound as highly stimulating and mildly entactogenic, lacking in typical psychedelic visual distortions. Many users report strong physical and tactile effects that serve to enhance libido and sexual pleasure. Many users note an unpleasant body load accompanies higher dosages. Some users also report sound distortion, which is also noted with the related compound, DiPT.
Very little is known about the pharmacological properties, metabolism and toxicity of 5-MeO-DiPT. It is relatively obscure and has a limited history of human use. It has been sold online as a research chemical. It is highly advised to use harm reduction practices if using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 References
5-MeO-DiPT, or 5-methoxy-N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 5-MeO-DiPT is substituted at R5 of its indole heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiPT).
5-MeO-DiPT is the N-substituted diisopropyl homolog of 5-MeO-MiPT.
5-MeO-DiPT's psychedelic effects are believed to come from its efficacy at the 5-HT2A receptor as a partial agonist, although additional mechanisms of action such as MAOIs may also be involved. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|| This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding it.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Spontaneous physical sensations
- Bodily pressures
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Headaches
- Stomach bloating - At higher dosages, this compound can induce severe stomach bloating within those who are susceptible to it. This can be partially to fully mitigated through the use of antacids.
- Pupil dilation
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 5-MeO-DiPT use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DiPT is a research chemical with very little history of human usage.
Anecdotal reports suggest that there are no negative health effects attributed to simply trying it by itself at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
Excessive doses have caused nausea, vomiting, agitation, decreased blood pressure, pupil dilation, increased heart rate, and hallucinations in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose. A 24-year-old man also died of this compound being administered into the colon.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
5-MeO-DiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-DiPT builds almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DiPT all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
- China: 5-MeO-DiPT is illegal in China.
- Denmark: 5-MeO-DiPT is illegal in Denmark.
- Greece: 5-MeO-DiPT is illegal in Greece.
- Germany: 5-MeO-DiPT is illegal in Germany.
- Japan: 5-MeO-DiPT is illegal in Japan.
- Latvia: 5-MeO-DiPT is illegal in Latvia.
- New Zealand: 5-MeO-DiPT can be considered an analogue of DMT, which makes it a Class C controlled drug in New Zealand.
- Singapore: 5-MeO-DiPT is illegal in Singapore.
- Sweden: 5-MeO-DiPT is illegal in Sweden.
- United Kingdom: 5-MeO-DiPT is a Class A drug in the UK as it is an ether of the drug 5-HO-DiPT, which is a Class A drug as a result of the tryptamine catch-all clause.
- United States: 5-MeO-DiPT is a Schedule 1 controlled substance.
- Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p176 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
- Shulgin, AT; Carter, MF. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1 Jan 1981, 4 (5), 363–369 | https://www.ncbi.nlm.nih.gov/pubmed/6949674
- The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811 / https://www.ncbi.nlm.nih.gov/pubmed/17223101
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 975-976.
- Misuse of Drugs Act 1971 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I/paragraph/3
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e